Related Experiment Video
Updated: Mar 30, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Establishing a Canadian national clinical trials network for kidney disease: proceedings of a planning workshop
Claudio Rigatto1, Michael Walsh2, Nadia Zalunardo3
1Department of Medicine, University of Manitoba, Winnipeg, MB Canada.
Abstract:
Knowledge generation through randomized controlled trials (RCTs) is critical to advance the medical evidence base, inform decision-making, and improve care and outcomes. Unfortunately, nephrology has typically lagged behind other medical specialties in this regard. The establishment of formal clinical trial networks can facilitate the successful conduct of RCTs and has significantly increased the number of RCTs performed worldwide in other medical specialties. No such formal network of nephrology trialists exists in Canada. On April 24, 2014, the Canadian Kidney Knowledge Translation and Generation Network (CANN-NET) Clinical Trials Committee held a stakeholder engagement meeting to address this gap and improve the nephrology clinical trial landscape in Canada. The meeting was held in Vancouver in association with the 2014 Canadian Society of Nephrology Annual General Meeting and was co-sponsored by the Kidney Foundation of Canada and CANN-NET. Attendees included nephrologists from university- and non-university-affiliated nephrology practices, administrators, and representatives from the Kidney Foundation of Canada. Through structured presentations and facilitated group discussions, the group explored the extent to which nephrology trials are currently happening in Canada, barriers to leading or participating in larger investigator-initiated trials, and strategies to improve clinical trial output in nephrology in Canada. The themes and action items arising from this meeting are discussed.
Insights
Canadian nephrology lacks a formal clinical trials network, hindering medical knowledge generation. A stakeholder meeting identified barriers and strategies to boost nephrology research and improve patient care through more randomized controlled trials (RCTs).
Area of Science:
- Nephrology
- Clinical Trials
- Health Services Research
Background:
- Randomized controlled trials (RCTs) are crucial for medical advancement but lag in nephrology.
- Canada lacks a formal network for nephrology clinical trialists.
- This gap impacts evidence generation and patient care in kidney diseases.
Purpose of the Study:
- To address the lack of a formal nephrology clinical trials network in Canada.
- To identify current nephrology trial activity, barriers, and strategies for improvement.
- To foster collaboration among Canadian nephrology stakeholders.
Main Methods:
- A stakeholder engagement meeting was convened by the Canadian Kidney Knowledge Translation and Generation Network (CANN-NET) Clinical Trials Committee.
- Attendees included nephrologists, administrators, and patient group representatives.
- Discussions focused on current trial landscape, leadership barriers, and enhancement strategies.
Main Results:
- Exploration of the current state of nephrology trials in Canada.
- Identification of significant barriers to leading or participating in investigator-initiated trials.
- Development of actionable strategies to enhance clinical trial output in Canadian nephrology.
Conclusions:
- Establishing a formal network is essential to advance nephrology research in Canada.
- Addressing identified barriers is key to increasing the number and impact of nephrology RCTs.
- Collaborative efforts are needed to improve the clinical trial landscape for kidney diseases.
More Related Videos
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Clinical Trials
There are four phases in a clinical trial. A phase one...
Kidney Transplant I: Introduction

